Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc. - Common Shares
(NQ:
XENE
)
58.79
+1.25 (+2.17%)
Streaming Delayed Price
Updated: 11:47 AM EDT, Apr 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
218,850
Open
57.68
Bid (Size)
58.73 (500)
Ask (Size)
58.85 (200)
Prev. Close
57.54
Today's Range
57.44 - 58.82
52wk Range
26.74 - 63.95
Shares Outstanding
63,562,303
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
April 07, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know
↗
March 27, 2026
This clinical-stage biotech advancing neurological therapies reported a notable insider sale as it progresses its drug pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
Performance
YTD
+32.1%
+32.1%
1 Month
-6.3%
-6.3%
3 Month
+39.6%
+39.6%
6 Month
+49.8%
+49.8%
1 Year
+108.3%
+108.3%
More News
Read More
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough
↗
March 13, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
XENON PHARMACEUTICALS INC (NASDAQ:XENE) Reports Q4 and Full-Year 2025 Results, Focus Remains on Upcoming Phase 3 Data for Azetukalner
↗
February 26, 2026
Via
Chartmill
Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know
↗
March 13, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
↗
March 13, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 12, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)
March 12, 2026
Via
Finterra
Topics
ETFs
Intellectual Property
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
March 10, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
March 10, 2026
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’
↗
March 09, 2026
Via
Stocktwits
Xenon Pharmaceuticals Announces Proposed Public Offering
March 09, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Top stock movements in today's session.
↗
March 09, 2026
Via
Chartmill
Monday's session: top gainers and losers
↗
March 09, 2026
Via
Chartmill
Gapping stocks in Monday's session
↗
March 09, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
March 09, 2026
Via
Chartmill
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
March 09, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
March 08, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
↗
February 23, 2026
Via
The Motley Fool
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake
↗
February 23, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million
↗
February 23, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50%
↗
February 23, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%
↗
February 23, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data
↗
February 19, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Frequently Asked Questions
Is Xenon Pharmaceuticals Inc. - Common Shares publicly traded?
Yes, Xenon Pharmaceuticals Inc. - Common Shares is publicly traded.
What exchange does Xenon Pharmaceuticals Inc. - Common Shares trade on?
Xenon Pharmaceuticals Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares?
The ticker symbol for Xenon Pharmaceuticals Inc. - Common Shares is XENE on the Nasdaq Stock Market
What is the current price of Xenon Pharmaceuticals Inc. - Common Shares?
The current price of Xenon Pharmaceuticals Inc. - Common Shares is 58.79
When was Xenon Pharmaceuticals Inc. - Common Shares last traded?
The last trade of Xenon Pharmaceuticals Inc. - Common Shares was at 04/09/26 11:47 AM ET
What is the market capitalization of Xenon Pharmaceuticals Inc. - Common Shares?
The market capitalization of Xenon Pharmaceuticals Inc. - Common Shares is 3.74B
How many shares of Xenon Pharmaceuticals Inc. - Common Shares are outstanding?
Xenon Pharmaceuticals Inc. - Common Shares has 4B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
